{"protocolSection":{"identificationModule":{"nctId":"NCT01102231","orgStudyIdInfo":{"id":"IFCT-0803"},"organization":{"fullName":"Intergroupe Francophone de Cancerologie Thoracique","class":"OTHER"},"briefTitle":"Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)","officialTitle":"Phase II Study of Pemetrexed + Cetuximab + Cisplatin With Concurrent Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)"},"statusModule":{"statusVerifiedDate":"2021-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2014-01","type":"ACTUAL"},"completionDateStruct":{"date":"2015-12","type":"ACTUAL"},"studyFirstSubmitDate":"2010-04-10","studyFirstSubmitQcDate":"2010-04-12","studyFirstPostDateStruct":{"date":"2010-04-13","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-01-06","resultsFirstSubmitQcDate":"2021-01-28","resultsFirstPostDateStruct":{"date":"2021-02-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-01-28","lastUpdatePostDateStruct":{"date":"2021-02-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Intergroupe Francophone de Cancerologie Thoracique","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Radiochemotherapy is a standard for the treatment of unresectable stage III non-small cell lung cancer. The investigators goal is to study the efficacy and the toxicity for a promising association of new agents (cetuximab and pemetrexed) with concurrent radiotherapy."},"conditionsModule":{"conditions":["Stage III Non-small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":106,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"A","type":"EXPERIMENTAL","description":"Chemoradiotherapy","interventionNames":["Drug: Chemotherapy","Drug: ERBITUX","Radiation: Radiotherapy"]}],"interventions":[{"type":"DRUG","name":"Chemotherapy","description":"Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)","armGroupLabels":["A"]},{"type":"DRUG","name":"ERBITUX","description":"The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes","armGroupLabels":["A"]},{"type":"RADIATION","name":"Radiotherapy","description":"66 Gy (2 Gy by fraction, 5 fractions by week)","armGroupLabels":["A"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Disease-Control Rate","description":"percentage of patients with disease control (complete response + partial response + stable disease) according to RECIST 1.1 criteria Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions.\n\nStable Disease (SD): Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for Progressive Disease (at least a 20% increase in the sum of diameters of target lesions).","timeFrame":"16 weeks after inclusion"}],"secondaryOutcomes":[{"measure":"18-month Overall Survival Rate","description":"Percentage of patient alive 18 months after registration","timeFrame":"18 months"},{"measure":"Progression Free Survival","description":"Progression-free survival is defined as time between date of inclusion and progression or all-cause death.\n\nProgression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","timeFrame":"52.3 months (median duration of follow-up)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* non-squamous stage III non-small cell lung cancer\n* measurable disease (RECIST 1.1)\n* ECOG performance status 0-1\n* normal organ and marrow function\n\nExclusion Criteria:\n\n* prior chest radiation therapy\n* history of any cancer other than NSCLC (except non-melanoma skin cancer or carcinoma in situ of the cervix) within the last five years.\n* Prior therapy with known specific inhibitors of the EGFR.\n* history of severe allergic reaction to prior therapy with monoclonal antibodies","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Jean Trédaniel, MD, PhD","affiliation":"IFCT, GH Paris Saint-Joseph","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Françoise Mornex, MD, PhD","affiliation":"IFCT, HCL Lyon-Sud","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Clinique de l'Europe","city":"Amiens","country":"France","geoPoint":{"lat":49.9,"lon":2.3}},{"facility":"Centre Hospitalier","city":"Annemasse","country":"France","geoPoint":{"lat":46.19439,"lon":6.23775}},{"facility":"CHU Besancon - Pneumologie","city":"Besançon","zip":"25000","country":"France","geoPoint":{"lat":47.24878,"lon":6.01815}},{"facility":"Bordeaux - Polyclinique Nord","city":"Bordeaux","zip":"33300","country":"France","geoPoint":{"lat":44.84124,"lon":-0.58046}},{"facility":"Caen - Centre François Baclesse","city":"Caen","zip":"14000","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"facility":"Caen - CHU Côte de Nacre","city":"Caen","zip":"14000","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"facility":"CH","city":"Chartres","country":"France","geoPoint":{"lat":48.44685,"lon":1.48925}},{"facility":"CH","city":"Cholet","country":"France","geoPoint":{"lat":47.05893,"lon":-0.87974}},{"facility":"CHU","city":"Clermont-Ferrand","country":"France","geoPoint":{"lat":45.77969,"lon":3.08682}},{"facility":"CH","city":"Colmar","country":"France","geoPoint":{"lat":48.08078,"lon":7.35584}},{"facility":"Clinique des Cèdres","city":"Cornebarrieu","country":"France","geoPoint":{"lat":43.64967,"lon":1.32588}},{"facility":"Dijon - CAC","city":"Dijon","zip":"21000","country":"France","geoPoint":{"lat":47.31344,"lon":5.01391}},{"facility":"CHU Grenoble","city":"Grenoble","zip":"38000","country":"France","geoPoint":{"lat":45.17869,"lon":5.71479}},{"facility":"Institut d'Oncologie Hartmann","city":"Levallois-Perret","country":"France","geoPoint":{"lat":48.89389,"lon":2.28864}},{"facility":"CHU (Hôpital Calmette) - Pneumologie","city":"Lille","zip":"59000","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"CH","city":"Longjumeau","country":"France","geoPoint":{"lat":48.69307,"lon":2.29431}},{"facility":"Clinique des 4 Pavillons","city":"Lormont","country":"France","geoPoint":{"lat":44.8765,"lon":-0.51919}},{"facility":"Hôpital Louis Pradel","city":"Lyon","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"facility":"Hôpital Nord","city":"Marseille","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Centre Hospitalier","city":"Montélimar","country":"France","geoPoint":{"lat":44.55468,"lon":4.75469}},{"facility":"CHU","city":"Nancy","country":"France","geoPoint":{"lat":48.68439,"lon":6.18496}},{"facility":"CH","city":"Nevers","country":"France","geoPoint":{"lat":46.98956,"lon":3.159}},{"facility":"Centre Hospitalier","city":"Niort","country":"France","geoPoint":{"lat":46.32313,"lon":-0.45877}},{"facility":"APHP - Hopital Tenon - Pneumologie","city":"Paris","zip":"75020","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Hôpital du Val de Grâce","city":"Paris","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Hôpital Saint-Joseph","city":"Paris","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Perpignan - Centre Catalan d'Oncologie","city":"Perpignan","zip":"66000","country":"France","geoPoint":{"lat":42.69764,"lon":2.89541}},{"facility":"HCL - Lyon Sud","city":"Pierre-Bénite","zip":"69495","country":"France","geoPoint":{"lat":45.70359,"lon":4.82424}},{"facility":"CHU","city":"Poitiers","country":"France","geoPoint":{"lat":46.58261,"lon":0.34348}},{"facility":"Centre Hospitalier","city":"Rambouillet","country":"France","geoPoint":{"lat":48.64374,"lon":1.82992}},{"facility":"Reims - CHU","city":"Reims","zip":"51092","country":"France","geoPoint":{"lat":49.26526,"lon":4.02853}},{"facility":"Institut Jean Godinot","city":"Reims","country":"France","geoPoint":{"lat":49.26526,"lon":4.02853}},{"facility":"Centre Frederic Joliot","city":"Rouen","country":"France","geoPoint":{"lat":49.44313,"lon":1.09932}},{"facility":"Centre Etienne Dolet","city":"Saint-Nazaire","country":"France","geoPoint":{"lat":47.27506,"lon":-2.2179}},{"facility":"Hôpitaux Universitaires - Nouvel Hôpital Civil","city":"Strasbourg","zip":"63000","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"Suresnes - Hopital Foch","city":"Suresnes","zip":"92151","country":"France","geoPoint":{"lat":48.87143,"lon":2.22929}},{"facility":"Tours - CHU","city":"Tours","zip":"37000","country":"France","geoPoint":{"lat":47.39484,"lon":0.70398}},{"facility":"Institut Gustave Roussy","city":"Villejuif","zip":"94800","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}}]},"referencesModule":{"references":[{"pmid":"20351327","type":"BACKGROUND","citation":"Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010 May 1;28(13):2181-90. doi: 10.1200/JCO.2009.26.2543. Epub 2010 Mar 29."},{"pmid":"21277474","type":"BACKGROUND","citation":"Tredaniel J, Mornex F, Barillot I, Diaz O, Hennequin C, Le Pechoux C, Lavole A, Giraud P, Souquet PJ, Teixeira L, Vaylet F, Zalcman G, Baudrin L, Morin F, Milleron B. [A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)]. Rev Mal Respir. 2011 Jan;28(1):51-7. doi: 10.1016/j.rmr.2010.06.027. Epub 2011 Jan 11. French."}],"seeAlsoLinks":[{"label":"IFCT official website","url":"http://www.ifct.fr"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Chemoradiotherapy + Cetuximab","description":"Chemotherapy + cetuximab + radiotherapy\n\nChemotherapy: Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)\n\nERBITUX: The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes\n\nRadiotherapy: 66 Gy (2 Gy by fraction, 5 fractions by week)"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"106"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"91"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"15"}]}],"dropWithdraws":[{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"3"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"3"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Did not received the treatment","reasons":[{"groupId":"FG000","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Chemoradiotherapy + Cetuximab","description":"Chemoradiotherapy\n\nChemotherapy: Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)\n\nERBITUX: The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes\n\nRadiotherapy: 66 Gy (2 Gy by fraction, 5 fractions by week)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"106"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57.32","lowerLimit":"30.6","upperLimit":"71.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"39"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"67"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"France","categories":[{"measurements":[{"groupId":"BG000","value":"106"}]}]}]},{"title":"Smoker","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"100"}]}]}]},{"title":"Stage","description":"Per the 7th edition of UICC/AJCC staging system. The T staging is determined by the size of primary tumour in long axis, or direct extent of the tumour into adjacent structures such as mediastinum or chest wall. The N classification descibes the degree of spread to regional lymph nodes. This remained unchanged in the 7th edition as the new data showed no change in node staging related survival. The M staging defines the presence of metastases beyond regional lymph nodes.\n\nStage IIIA: T1 to T3N2M0 and T4N1M0; Stage IIIB: T1 to T4N3M0, Stage IV: T1 to T4 N1toN3 M1","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"IIIA","measurements":[{"groupId":"BG000","value":"53"}]},{"title":"IIIB","measurements":[{"groupId":"BG000","value":"51"}]},{"title":"IV","measurements":[{"groupId":"BG000","value":"2"}]}]}]},{"title":"Histological subtype","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Sarcomatoid","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"Adenosquamous","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Adenocarcinoma without bronchoalveolar component","measurements":[{"groupId":"BG000","value":"82"}]},{"title":"Non Small Cell","measurements":[{"groupId":"BG000","value":"14"}]},{"title":"Neuroendocrine carcinoma","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Non Squamous Non Small Cell","measurements":[{"groupId":"BG000","value":"6"}]}]}]},{"title":"ECOG Performance status","description":"PS0 : fully active, able to carry on all pre-disease performance without restriction PS1 : Restricted in physically strenuous but ambulatory and able to carry out work of a light or sedentary nature, e.g. light house work, office work","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"PS = 0","measurements":[{"groupId":"BG000","value":"63"}]},{"title":"PS = 1","measurements":[{"groupId":"BG000","value":"43"}]}]}]},{"title":"Unresectability cause","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Anatomical","measurements":[{"groupId":"BG000","value":"100"}]},{"title":"Functional","measurements":[{"groupId":"BG000","value":"6"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Disease-Control Rate","description":"percentage of patients with disease control (complete response + partial response + stable disease) according to RECIST 1.1 criteria Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions.\n\nStable Disease (SD): Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for Progressive Disease (at least a 20% increase in the sum of diameters of target lesions).","populationDescription":"Eligible population","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"16 weeks after inclusion","groups":[{"id":"OG000","title":"Chemoradiotherapy + Cetuximab","description":"Chemoradiotherapy\n\nChemotherapy: Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)\n\nERBITUX: The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes\n\nRadiotherapy: 66 Gy (2 Gy by fraction, 5 fractions by week)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"OTHER","paramType":"Proportion difference","paramValue":"0.905","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.846","ciUpperLimit":"0.964"}]},{"type":"SECONDARY","title":"18-month Overall Survival Rate","description":"Percentage of patient alive 18 months after registration","populationDescription":"Eligible population","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participant","timeFrame":"18 months","groups":[{"id":"OG000","title":"Chemoradiotherapy + Cetuximab","description":"Chemoradiotherapy\n\nChemotherapy: Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)\n\nERBITUX: The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes\n\nRadiotherapy: 66 Gy (2 Gy by fraction, 5 fractions by week)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.4","lowerLimit":"32.6","upperLimit":"51.9"}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival","description":"Progression-free survival is defined as time between date of inclusion and progression or all-cause death.\n\nProgression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"52.3 months (median duration of follow-up)","groups":[{"id":"OG000","title":"Chemoradiotherapy + Cetuximab","description":"Chemotherapy + cetuximab + radiotherapy\n\nChemotherapy: Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)\n\nERBITUX: The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes\n\nRadiotherapy: 66 Gy (2 Gy by fraction, 5 fractions by week)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","lowerLimit":"11.2","upperLimit":"18.8"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse event were collected for a patient from the date of signature of his inform consent form until 30 days after the end of his study treatment. Deaths were collected through study completion.","eventGroups":[{"id":"EG000","title":"Chemoradiotherapy + Cetuximab","description":"Chemotherapy + cetuximab + radiotherapy\n\nChemotherapy: Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)\n\nERBITUX: The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes\n\nRadiotherapy: 66 Gy (2 Gy by fraction, 5 fractions by week)","deathsNumAffected":51,"deathsNumAtRisk":102,"seriousNumAffected":26,"seriousNumAtRisk":102,"otherNumAffected":100,"otherNumAtRisk":102}],"seriousEvents":[{"term":"Phlebitis superficial","organSystem":"Vascular disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Pulmonary embolism","organSystem":"Vascular disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":102}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Asthenia","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Fatigue","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"General physical health deterioration","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":102}]},{"term":"Death","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Hyperthermia","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Malaise","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Pyrexia","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Hemoglobin decreased","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Platelet count decreased","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Hemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":102}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Respiratory tract infection","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":102}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Bone marrow failure","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Febrile bone marrow aplasia","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":102}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Carotid artery aneurysm","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Eye pain","organSystem":"Eye disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":102}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Faecaloma","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":102}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":102}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":102}]},{"term":"Aphasia","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Hematuria","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":102}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"decreased appetite","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Dehydratation","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Hypocalcemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Hypokalemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":102}]},{"term":"device related infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":102}]},{"term":"Sepsis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Infective exacerbation of chronic obstructive airways disease","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":102}]}],"otherEvents":[{"term":"Alopecia","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":14,"numAtRisk":102}]},{"term":"Asthenia","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":250,"numAffected":78,"numAtRisk":102}]},{"term":"Chest pain","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":47,"numAffected":19,"numAtRisk":102}]},{"term":"Edema limb","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":102}]},{"term":"Fever","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":14,"numAtRisk":102}]},{"term":"Vertigo","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":102}]},{"term":"Weight loss","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":19,"numAtRisk":102}]},{"term":"Hemoglobin decreased","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":217,"numAffected":63,"numAtRisk":102}]},{"term":"Neutrophil count decreased","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":234,"numAffected":80,"numAtRisk":102}]},{"term":"Platelet count decreased","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":178,"numAffected":62,"numAtRisk":102}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":94,"numAffected":38,"numAtRisk":102}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":10,"numAtRisk":102}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":94,"numAffected":39,"numAtRisk":102}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":13,"numAtRisk":102}]},{"term":"Hemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":102}]},{"term":"Neuropathy","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":102}]},{"term":"Paresthesia","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":7,"numAtRisk":102}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":9,"numAtRisk":102}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":10,"numAtRisk":102}]},{"term":"Anorexia","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":106,"numAffected":45,"numAtRisk":102}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":83,"numAffected":39,"numAtRisk":102}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":23,"numAtRisk":102}]},{"term":"dysgueusia","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":102}]},{"term":"dysphagia","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":181,"numAffected":65,"numAtRisk":102}]},{"term":"Gastralgia","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":102}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":217,"numAffected":76,"numAtRisk":102}]},{"term":"Oral mucosal irritation","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":92,"numAffected":44,"numAtRisk":102}]},{"term":"Pyrosis","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":102}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":69,"numAffected":37,"numAtRisk":102}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":8,"numAtRisk":102}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":80,"numAffected":23,"numAtRisk":102}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":58,"numAffected":27,"numAtRisk":102}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":92,"numAffected":30,"numAtRisk":102}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":21,"numAtRisk":102}]},{"term":"Folliculitis","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":124,"numAffected":36,"numAtRisk":102}]},{"term":"Paronychia","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":102}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":102}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":114,"numAffected":32,"numAtRisk":102}]},{"term":"Skin disorder","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":16,"numAtRisk":102}]},{"term":"Hypokalemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":7,"numAtRisk":102}]},{"term":"Mycosis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":102}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Non randomized study"},"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Communications Officer","organization":"IFCT","email":"contact@ifct.fr","phone":"+33156811045"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D004358","term":"Drug Therapy"},{"id":"D000068818","term":"Cetuximab"},{"id":"D011878","term":"Radiotherapy"}],"ancestors":[{"id":"D013812","term":"Therapeutics"},{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"}]}},"hasResults":true}